FDA cleared the Xpert® Hemorrhagic Fever Panel from Cepheid on Oct 30, 2026 under K262971, a traditional 510(k). The device falls under product code QVR, Multiplex Nucleic Acid Detection System For Biothreat Agents, regulated at 21 CFR 866.4000 as a Class 2 device. The review panel was Immunology.

FDA logged the submission as received on Aug 26, 2026. The decision came 65 days later, inside the 90 FDA-day goal for a 510(k).

Cepheid has 4 other decisions in the tracker over the last 12 months: K261336 (Xpert Respiratory Panel), K261362 (Xpert Hemorrhagic Fever), K253653 (Xpert Hemorrhagic Fever), K251721 (Xpert GI Panel).